CPT Code 96401 Denials: 5 Billing Mistakes That Cost an Oncology Practice $14,000 Per Month

The CPT code for chemotherapy administration via push, subcutaneous or intramuscular with a non hormonal anti neoplastic drug is 96401. The reason why is that sometimes 96401 is unique because the same drug may get approved and at other times it may not get approved entirely based on the reason for which it was given. This one little thing leads to much more denial than most push injection practices would expect.

We recently did a complete review for a client at Infusion Billing Services. Their claim to 96401 was being denied at a high and expensive rate. This case study provides an explanation of the rules of 96401 that not everyone was following. It also includes the fixes that helped cut down rejections and get payments quicker.

Client Snapshot

Our client was a medium sized oncology infusion center with 2 Locations. They performed chemotherapy every month on approximately 150 patients. 96401 was billed frequently for both cancer and non cancer indications. Medicare, various commercial plans and Medicaid coverage accounted for the payer mix. Nearly 40% of all claims were paid for by Medicare. We’ve been reviewing the billing history for nine months prior to engagement. This included over 600 separate 96401 line items by payers. Initially, the rejection rate for 96401 was 26 per center. The payment turnaround for approved claims was also almost 50 days on average.

Denial Reason 1: Drug Misclassified as a Routine Therapeutic Injection

96401 is only valid when the drug is used for chemotherapy purposes. The exact same push injection can qualify as CPT 96372 instead. This happens when the drug is given for a non cancer reason. Payers reviewed the diagnosis and downgraded 96401 to a lower paying code.

Problem:

• Drug qualified as chemo for one visit, not another
• Coders defaulted to 96401 without checking the indication
• Diagnosis on file did not support chemotherapy intent

Fix:

• Flagged dual purpose drugs for indication review first
• Confirmed cancer intent before assigning the 96401 code
• Trained coders on drug specific indication rules

This single fix resolved the largest and most confusing rejection pattern.

Denial Reason 2: Same Drug Billed Under the Wrong Diagnosis Category

Certain drugs are approved for both cancer and non cancer use. One example is a bone modifying agent used in two distinct ways. The cancer version supports 96401, the non cancer version does not. Several claims used the cancer administration code for a benign diagnosis.

Problem:

• Non cancer diagnosis was paired with 96401 billing
• Dual indication drug was coded the same way each time
• Diagnosis category was not checked against drug purpose

Fix:

• Built a dual indication drug list for reference
• Matched diagnosis category to the correct code each visit
• Reviewed indication specific payer policies before billing

This fix stopped a repeat error that had been hiding in plain sight.

Denial Reason 3: Multiple Units Billed for a Single Push Session

96401 is payable only once per encounter, regardless of injection count. Some visits involved more than one push of the same drug. Staff billed additional units for each separate push administered. This exceeded the payer’s medically unlikely edit for the code.

Problem:

• More than one unit was billed for one encounter
• Multiple pushes were coded as separate billable units
• Medically unlikely edit limits were not checked first

Fix:

• Limited 96401 to one unit per encounter by rule
• Reviewed medically unlikely edit limits before submission
• Trained staff on single push per session billing logic

Correcting this stopped an automatic rejection tied directly to unit limits.

Denial Reason 4: Drug Not Listed on the Payer Approved Chemotherapy List

Some payers publish a specific list of drugs covered under 96401. A claim was denied when the administered drug was not on that list. This happened even when the diagnosis clearly supported cancer treatment. The drug itself simply was not recognized under that payer’s policy.

Problem:

• Administered drug was missing from the payer drug list
• Coverage policy was not checked before the visit occurred
• Claim was billed as if approval was already confirmed

Fix:

• Checked payer approved drug lists before scheduling visits
• Flagged unlisted drugs for prior authorization in advance
• Updated the internal drug list as payer policies changed

Checking coverage in advance prevented a denial that was hard to appeal.

Denial Reason 5: Missing Modifier 25 on a Same Day Office Visit

Patients sometimes had a separate office visit on the same day. Without modifier 25, the visit was bundled into the 96401 charge. This meant the evaluation and management service went completely unpaid. Payers require clear proof the visit was significant and separate.

Problem:

• Office visit was billed without the required modifier 25
• Documentation did not show a separate, significant service
• Visit and injection were treated as one bundled charge

Fix:

• Required modifier 25 on all qualifying same day visits
• Documented the separate reason for the office visit clearly
• Reviewed same day claims before submission for completeness

This fix recovered visit revenue that had been lost to bundling.

Financial Recovery Results

After these fixes were applied, claim performance improved across every metric. The table below shows the clear shift before and after the review.

Faster turnaround also improved monthly cash flow for the practice. Fewer rejected claims meant less staff time spent on rework. These results show that 96401 denials were mostly preventable coding errors.

Key Takeaways

• Confirm chemotherapy intent before assigning the 96401 code
• Match diagnosis category correctly for dual indication drugs
• Bill only one 96401 unit per encounter, regardless of pushes
• Check payer drug lists and coverage policy before scheduling
• Apply modifier 25 correctly on qualifying same day visits

Conclusion

There are rules specific to this code that must be followed in order to have accurate billing for 96401. All drug indications, unit limits, coverage lists and modifiers are significant. It’s a known fact that each solution in itself significantly reduced the rejections in this case. Once these problems were rectified, payments were also quicker. Let us help you when your practice is consistently denied 96401 or is slow to pay. Infusion Billing Services can pinpoint the reason for each rejection. We make permanent solutions, so the money stays in your practice. Call Infusion Billing Services today for an in-depth denial audit and review. Begin to cut down on 96401 rejections and shorten the payment turnaround.